Andrew Hollman Meyer, Chief Business Officer at Janux Therapeutics, Inc. (JANX), sold 6,266 shares at $31.95 ($200K) on 2025-05-01, disclosed to the SEC on 2025-05-02.
Scheduled sale ($200k) by Chief Business Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $31.95 | 2,933 | $94K | 46.7% |
| 2 | $31.95 | 2,933 | $94K | 46.7% |
| 3 | $32.60 | 400 | $13K | 6.5% |
| Total | $31.99 avg | 6,266 | $200K | 100% |
| Filing → |
| JANX | SELL | 2025-11-14 | $100K | — | Filing → |
| JANX | SELL | 2025-10-30 | $1.0M | — | Filing → |
| JANX | SELL | 2025-04-23 | $100K | — | Filing → |